Medigen Vaccine Biologics Corp (高端疫苗) yesterday said it would be ready to manufacture 20 million doses of its experimental COVID-19 vaccine next year if it gains emergency use authorization from the government by June.
“That would be our maximum annual vaccine production capacity at our cell-culture manufacturing facility with GMP certification in Hsinchu,” Medigen spokesman Leo Lee (李思賢) told the Taipei Times by telephone.
Twenty million doses would be enough to vaccinate 10 million people, as each person would need two doses, Lee said.
Photo: CNA
Medigen on Friday signed a memorandum of understanding with Vietnam’s National Institute of Hygiene and Epidemiology to provide 3 million to 10 million vaccine doses to help Vietnam fight the COVID-19 pandemic, the company told a news conference in Taipei on Monday.
According to the memorandum, the phase 2 trial of Medigen’s COVID-19 vaccine would begin early next year and include 3,000 participants in Taiwan and Vietnam, Medigen chief executive officer Charles Chen (陳燦堅) told the news conference.
Lee yesterday said the phase 2 trial would be conducted simultaneously in Taiwan and Vietnam, and participants would include at least 1,300 in Taiwan.
The company plans to apply to the Food and Drug Administration and the Vietnamese regulator next month, he added.
Although the pandemic has been controlled in Taiwan, vaccines and drugs are deemed essential in fighting the disease. Some locally developed vaccine candidates, including those by Medigen, Adimmune Corp (國光生技) and United Biomedical Inc (聯亞生技), have undergone phase 1 human trials.
Medigen has enrolled 45 participants aged 20 to 50 for its phase 1 trial in Taiwan.
They have been divided into three groups that receive low, medium or high doses, the company said.
“We have not seen any serious adverse reactions among the enrolled people,” Lee said.
The company’s decision to expand the scope of its human trials in Vietnam follows its ongoing phase 3 trials for its enterovirus 71 vaccine there, which has laid a firm foundation, Lee said.
There are also strong trade ties between Taiwan and Vietnam, where many Taiwanese companies operate, he said.
In related news, TTY Biopharm Co (台灣東洋藥品) yesterday said it has terminated a bid to gain Bio-NTech SE’s authorization to sell its mRNA-based COVID-19 vaccine in Taiwan.
TTY Biopharm last month announced its intention to negotiate with Bio-NTech over the mRNA-based vaccine, but said that the two sides had failed to reach an agreement on the authorization terms, the company said in a filing with the Taiwan Stock Exchange.
The company did not elaborate.
European Central Bank (ECB) President Christine Lagarde is expected to step down from her role before her eight-year term ends in October next year, the Financial Times reported. Lagarde wants to leave before the French presidential election in April next year, which would allow French President Emmanuel Macron and German Chancellor Friedrich Merz to find her replacement together, the report said, citing an unidentified person familiar with her thoughts on the matter. It is not clear yet when she might exit, the report said. “President Lagarde is totally focused on her mission and has not taken any decision regarding the end of
French President Emmanuel Macron told a global artificial intelligence (AI) summit in India yesterday he was determined to ensure safe oversight of the fast-evolving technology. The EU has led the way for global regulation with its Artificial Intelligence Act, which was adopted in 2024 and is coming into force in phases. “We are determined to continue to shape the rules of the game... with our allies such as India,” Macron said in New Delhi. “Europe is not blindly focused on regulation — Europe is a space for innovation and investment, but it is a safe space.” The AI Impact Summit is the fourth
CONFUSION: Taiwan, Japan and other big exporters are cautiously monitoring the situation, while analysts said more Trump responses ate likely after his loss in court US trading partners in Asia started weighing fresh uncertainties yesterday after President Donald Trump vowed to impose a new tariff on imports, hours after the Supreme Court struck down many of the sweeping levies he used to launch a global trade war. The court’s ruling invalidated a number of tariffs that the Trump administration had imposed on Asian export powerhouses from China and South Korea to Japan and Taiwan, the world’s largest chip maker and a key player in tech supply chains. Within hours, Trump said he would impose a new 10 percent duty on US imports from all countries starting on
STRATEGIC ALLIANCE: The initiative is aimed at protecting semiconductor supply chain resilience to reduce dependence on China-dominated manufacturing hubs India yesterday joined a US-led initiative to strengthen technology cooperation among strategic allies in a move that underscores the nations’ warming ties after a brief strain over New Delhi’s unabated purchase of discounted Russian oil. The decision aligns India closely with Washington’s efforts to build secure supply chains for semiconductors, advanced manufacturing and critical technologies at a time when geopolitical competition with China is intensifying. It also signals a reset in relations following friction over energy trade and tariffs. Nations that have joined the Pax Silica framework include Japan, South Korea, the UK and Israel. “Pax Silica will be a group of nations
RSS